Longevity Blogs

Discover insightful articles on health, wellness, and the habits that support a longer, stronger life.

Showing 13 to 24 of 34 articles

Immune Age Revisited: New 2026 Biomarkers Reveal Sex-Specific Biological Decline

From Chronological to Cellular: The Rise of Immune Aging Clocks The landscape of biological age estimation has undergone a fundamental recalibration this spring...

May 24, 2026
0 47

Is the "Blueprint Protocol" for you?

The Dont Die Blueprint protocol that is free and available for everyone online to follow the perfect human diet. Review its research ground and discuss the viability for most people.

May 21, 2026
0 32

Oral Senolytics Step Out of the Lab: Phase II Trial Shows Fisetin Mitigates Physical Impairment

Oral Senolytics Step Out of the Lab: Phase II Trial Shows Fisetin Mitigates Physical Impairment The landscape of geroscience is undergoing a structural shift, m...

May 19, 2026
0 43

Blood Tests, Mitochondria, and Targeted Pilots: Three Groundbreaking Shifts in Longevity Science

A Precise Pivot in Longevity Research As of mid-May 2026, the geroscience landscape is undergoing a quiet but decisive transition. While earlier phases of longe...

May 17, 2026
0 49

The Longevity Pivot: Why IL-11 Inhibition Is Leading the Anti-Fibrotic Wave in Geroscience

From Cellular Clearance to Tissue Protection For years, the geroscience community has operated under a straightforward therapeutic premise: if aging cells drive...

May 16, 2026
0 44

Precision Pivots: How ADC Senolytics and Controlled Reprogramming Are Defining 2026 Geroscience

The 2026 Paradigm Shift: From Broad Action to Molecular Fidelity As the geroscience field enters mid-2026, a distinct evolution is reshaping how researchers app...

May 15, 2026
0 52

Beyond HbA1c: How Glucose Variability Accelerates Vascular Aging

Beyond HbA1c: How Glucose Variability Accelerates Vascular Aging For years, metabolic health assessments have leaned heavily on static metrics like hemoglobin A...

May 14, 2026
0 39

The Muscle Paradox: GLP-1 Therapy, Lean Mass Loss, and Emerging Skeletal Risks

The Muscle Paradox: GLP-1 Therapy, Lean Mass Loss, and Emerging Skeletal Risks While GLP-1 receptor agonists such as semaglutide and tirzepatide remain dominant...

May 13, 2026
0 35

2026 regulatory–payer blueprint for geroscience therapies: biomarkers, CMC, and Medicare coverage

Why 2026 is a turning point for getting geroscience therapies to older adults As of May 12, 2026, developers of therapies aimed at aging biology face a regulato...

May 12, 2026
0 62

The doxycycline ‘on’ switch: practical safety and monitoring questions for ER‑100’s first human doses

Why the induction method matters Life Biosciences’ ER‑100, the first partial‑reprogramming therapy to receive an FDA IND, uses a doxycycline‑inducible system to...

May 11, 2026
0 52

Inside ER‑100’s eye‑first strategy: intravitreal tradeoffs, monitoring, and what to watch in the Phase 1 protocol

Summary In early 2026 Life Biosciences received FDA clearance of an IND for ER‑100, opening a Phase 1, first‑in‑human, single‑dose safety trial in open‑angle gl...

May 9, 2026
0 53

Designing trial endpoints and biomarkers for ER‑100 versus D+Q and rapamycin: matching measures to mechanism

Why different geroscience tools demand different trials The partial epigenetic reprogramming approach represented by ER‑100 (AAV2‑delivered OSK) and two classes...

May 9, 2026
0 65

Join the mailing list

Get new posts from Longevity Blogs

Be the first to know when fresh articles are published.

No emails will be sent yet. Your signup is saved for future updates.